Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

3.720 +0.020 (+0.55%)
Streaming Delayed Price Updated: 10:23 AM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Preclinical Study Finds a Way to Reverse Symptoms of Parkinson’s in Mice
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
Via Investor Brand Network
Why Public Interest in Mitochondrial Function Testing is Growing
Via Investor Brand Network
Q2 Virtual Investor Summit: Presentations Available Now
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
Via Stocktwits
Study Finds Kids with MS Biologically Age Faster Than Those Without It
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Rob Etherington to Present at June 10 Investor Summit Virtual
Via Investor Brand Network
Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
Via ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Study Links Autism to Increased Risk of Developing Parkinson’s Disease
Via Investor Brand Network
Researchers Discover Potential Missing Connection Between EBV and Multiple Sclerosis
Via Investor Brand Network
Eye Exam Could Help in Detecting Parkinson’s Disease Early, Study Suggests
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports Q1 Results, Advances CNM-Au8 Toward Potential Accelerated Approval for ALS
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in D. Boral Capital Global Conference on May 14
Via Investor Brand Network
Scientists ID Bacteria That Could Be Behind Multiple Sclerosis Development
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Evidence of Remyelination, Cognitive and Visual Gains in MS Trial
Via Investor Brand Network
Study Suggests Possible Link Between ADHD and Heightened Dementia Risk
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) to Share CNM-Au8(R) Progress at Jones Las Vegas Conference
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference on April 9
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available for On-Demand Viewing
Via Investor Brand Network
New Study Finds Possible Explanation for Higher Parkinson’s Prevalence in Men
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference
Via Investor Brand Network
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025
SALT LAKE CITY - March 25, 2025 (NEWMEDIAWIRE) - Clene Inc. (NASDAQ: CLNN), along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage... 
Via TheNewswire.com
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.